Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness
Julie Leca, … , Sophie Vasseur, Richard Tomasini
Julie Leca, … , Sophie Vasseur, Richard Tomasini
Published October 4, 2016
Citation Information: J Clin Invest. 2016;126(11):4140-4156. https://doi.org/10.1172/JCI87734.
View: Text | PDF
Research Article Cell biology Oncology

Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness

  • Text
  • PDF
Abstract

The intratumoral microenvironment, or stroma, is of major importance in the pathobiology of pancreatic ductal adenocarcinoma (PDA), and specific conditions in the stroma may promote increased cancer aggressiveness. We hypothesized that this heterogeneous and evolving compartment drastically influences tumor cell abilities, which in turn influences PDA aggressiveness through crosstalk that is mediated by extracellular vesicles (EVs). Here, we have analyzed the PDA proteomic stromal signature and identified a contribution of the annexin A6/LDL receptor-related protein 1/thrombospondin 1 (ANXA6/LRP1/TSP1) complex in tumor cell crosstalk. Formation of the ANXA6/LRP1/TSP1 complex was restricted to cancer-associated fibroblasts (CAFs) and required physiopathologic culture conditions that improved tumor cell survival and migration. Increased PDA aggressiveness was dependent on tumor cell–mediated uptake of CAF-derived ANXA6+ EVs carrying the ANXA6/LRP1/TSP1 complex. Depletion of ANXA6 in CAFs impaired complex formation and subsequently impaired PDA and metastasis occurrence, while injection of CAF-derived ANXA6+ EVs enhanced tumorigenesis. We found that the presence of ANXA6+ EVs in serum was restricted to PDA patients and represents a potential biomarker for PDA grade. These findings suggest that CAF–tumor cell crosstalk supported by ANXA6+ EVs is predictive of PDA aggressiveness, highlighting a therapeutic target and potential biomarker for PDA.

Authors

Julie Leca, Sébastien Martinez, Sophie Lac, Jérémy Nigri, Véronique Secq, Marion Rubis, Christian Bressy, Arnauld Sergé, Marie-Noelle Lavaut, Nelson Dusetti, Céline Loncle, Julie Roques, Daniel Pietrasz, Corinne Bousquet, Stéphane Garcia, Samuel Granjeaud, Mehdi Ouaissi, Jean Baptiste Bachet, Christine Brun, Juan L. Iovanna, Pascale Zimmermann, Sophie Vasseur, Richard Tomasini

×

Figure 5

CAF-derived ANXA6+ EVs enhance cancer cell aggressiveness.

Options: View larger image (or click on image) Download as PowerPoint
CAF-derived ANXA6+ EVs enhance cancer cell aggressiveness.
(A) Western b...
(A) Western blot of the indicated proteins in total cell lysate (TCL, left panel) or high-speed pellet (HSP) extractions (right panel) established from shCtr CAFs, macrophages (M), shCtr CAFs* cocultured with macrophages, or macrophages* cocultured with shCtr CAFs. Marker specificity of each antibody used in immunoblots is labeled by *. Data are representative of 3 independent experiments. ER, endoplasmic reticulum. (B) Coimmunoprecipitation of LRP1 with ANXA6 and TSP1 in protein extracts from HSP extractions established from macrophages cocultured with shCtr CAFs or macrophages cocultured with shANXA6-1 CAFs. HSPs were used as loading control. Data are representative of 3 independent experiments (C) Graphical representation of culture protocol for measuring PANC-1 migration ability (median ± interquartile range, n = 3). *P < 0.05, **P < 0.01, Mann-Whitney U test. (D) PANC-1 migration assay as in C with HSPs from CAFs infected with shCtr or shANXA6s under physiopathologic conditions (median ± interquartile range, n = 3). **P < 0.01, Mann-Whitney U test. (E) Rescue of PANC-1 migration assay designed as in C using HSPs from CAFs infected with shCtr under physiopathologic conditions (median ± interquartile range, n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, Mann-Whitney U test. (F) PANC-1 orthotopic xenografts in mice following i.p. injections of PBS (n = 7), or HSP shCtr (n = 4) or HSP shANXA6-1 (n = 8). Two months after cell injection, mice were euthanized and tumors dissected and weighed (median ± interquartile range). *P < 0.05, Mann-Whitney U test. (G) Quantification of PKH26+ PANC-1 cells after culturing for the indicated time with PKH26-stained HSPs from CAFs infected with shCtr or shANXA6s cultured under physiopathologic conditions (median ± interquartile range, n = 3). *P < 0.05, Mann-Whitney U test. (C–E) Data are expressed as fold increase compared with PANC-1 alone.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts